



OUTSOURCING

Emerging Clinical Trial Locations

Market dynamics and the changing healthcare and regulatory environment

By Paul Taylor Ph.D. MBA

Paul Taylor

Paul Taylor is an independent market analyst for the medical industry with a BSc and PhD in Biochemistry from the University of Liverpool and an MBA from Oxford Brookes University. Dr Taylor has worked in the medical industry as a senior marketing executive for 20 years creating and implementing strategic business and marketing plans for major multinational medical device companies before establishing himself as an independent research analyst.

For the last ten years Dr Taylor has focused on the structure, organization and functioning of the European healthcare systems with particular focus on reimbursement systems, analyzing specific European product market segments and advising/preparing strategic business and marketing plans for international pharmaceutical, medical devices and healthcare technology companies.

Copyright © 2009 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Emerging clinical trial locations -

Executive summary	16	
Introduction	16	
Conducting clinical trials in emerging markets	17	
India	18	
China	19	
Latin America	20	
Central and Eastern Europe	21	
Chapter 1	Introduction	24
Summary		24
Introduction		25
Generic competition		25
Intellectual property protection		25
Managing regulatory compliance		27
Cost containment and government funding restrictions		28
Obtaining and maintaining competitive advantage		28
Recruitment and retention of a skilled workforce		29
Improvement to R&D productivity		30
High risks and costs associated with drug development		30
Escalating costs of clinical trials		30
Global increase in the number of clinical trials conducted		34
Longer R&D timelines		34
Increased attrition rates during R&D		37
Clinical trial study design and planning		38
Clinical trial study design		38
Clinical trial study protocol		38
Clinical trial sponsors		38
Identifying and recruiting patients		39
Role of CROs		39
Information technology and new technology platforms		40
Drivers of development		40
Advantages associated with EDC		40
Advantages of electronic Clinical Trial Management Systems (CTMS)		41
Cost saving		42

Issues and challenges	42
Electronic records and signatures	42
Integration and linkage of electronic systems	43
Security and confidentiality of patient data	43

Chapter 2 Conducting clinical trials in emerging markets 46

Summary	46
Introduction	47
Market drivers	49
Rapid recruitment of patients and clinical trial investigators	49
Significant cost benefits	51
Improving transparency and efficiency of regulatory systems	52
Harmonization and standardization of regulatory requirements	53
Expansion of CROs	54
Conducive hospital infrastructure and healthcare systems	56
Enhanced clinical site effectiveness	57
Future commercial value	58
Key barriers	59
Concerns over the clinical trial transparency	60
Publication bias	61
Selective reporting	62
Duplicate publication	62
Conflict of interest	62
Availability of demographic and epidemiology data	62
Critical components concerning capacity building	63
Assimilation of individual national regulations and guidelines	66
United States	66
Japan	67
European Union	68
Language translation	69
Ethical challenges	69
Health needs of the population under study	70
Respect for potential and enrolled subjects	70
Ethical oversight	71
Lack of review by institutional review board (IRB)	71
Absence of informed consent	72
Scientific validity	73
Inadequate protection of intellectual property	73
Clinical trial logistics	74
Import licenses and applications	74
Customs regulations	75
Storage, handling and distribution	75
Selecting an appropriate CRO	76
Patient enrolment	79
Site selection	80

	Site activation	80
	Patient recruitment	80
Chapter 3	India	84
	Summary	84
	Introduction	85
	Geographic	85
	Political	85
	Economic	85
	Market dynamics	85
	Vital statistics	85
	Population statistics	87
	Epidemiology and prevalence of major disease	88
	Pharmaceutical market	89
	Biotechnology market	92
	CRO market	94
	Clinical trial market	97
	Geographic focus of the Indian clinical research industry	97
	Market drivers	100
	Population ethnicity and genetic diversity	100
	Large complement of trained medical specialists in India	101
	Significant cost savings	102
	Government incentives	103
	Creation of the Clinical Trials Registry – India (CTRI)	103
	Sophisticated logistics and clinical research infrastructure	104
	Comprehensive IT and IT enabled support (ITES) base	105
	Key barriers	106
	Ethical issues	106
	Lack of experienced investigators	107
	Inability to detect and monitor ADRs	107
	Bribery and corruption	107
	Healthcare	108
	Healthcare system	108
	National level	108
	State level	108
	Regional level	108
	District level	109
	Sub-divisional/Taluka level	110
	Community level	110
	Primary health centre (PHC) level	110
	Sub health centre (SHC) level	110
	Hospital resources	110
	Regulation and legislation	112
	Regulatory authorities	112
	The Ministry of Health and Family Welfare	112
	Central Drug Standard Control Organization (CDSCO)	115

Monitor compliance of SFDA GCP with ICH GCP	153
Healthcare	154
Healthcare system	154
Overview	154
Healthcare reforms	156
Healthcare institutions	157
Hospital resources	158
Regulation	160
Regulatory authorities	160
State Food and Drug Administration (SFDA)	160
Department of drug registration	161
Clinical trial regulation	161
Application and approval of the new drug clinical trial study	162
Registration approval for the manufacture of the new drug for market	163
Legislation	165
Patent Law and WTO TRIPS	165
Drug Administration Law of the People's Republic of China	168
Outlook	172

Chapter 5 Latin America 174

Summary	174
Introduction	175
Geographic	175
Brazil	175
Argentina	175
Mexico	176
Political	176
Brazil	176
Argentina	176
Mexico	177
Economic	177
Brazil	177
Argentina	177
Mexico	177
Market dynamics	178
Vital statistics - Brazil	178
Population statistics	178
Epidemiology and prevalence of major disease	178
Vital statistics - Argentina	179
Population statistics	179
Epidemiology and prevalence of major diseases	179
Vital statistics - Mexico	180
Population statistics	180
Epidemiology and prevalence of major disease	180
Pharmaceutical market	182

CRO market	185
Clinical trial market	186
Market drivers	188
Significant cost savings	188
High concentration of population in urban centers	188
High ethnic diversity	189
High patient enrolment, compliance and retention rates	189
A major growing Latin American pharmaceutical market	190
Reverse seasons advantages	190
Commonality of Spanish language	190
Accessibility to medical professionals and clinical trial investigators	190
National clinical trials register – Argentina	191
Key barriers	191
Concerns over intellectual property protection	191
Inconsistent regulatory environment	192
Cultural challenges and issues	193
Healthcare	194
Healthcare system- Brazil	194
Hospital resources - Brazil	194
Healthcare system - Argentina	195
Hospital resources - Argentina	195
Healthcare system - Mexico	196
Hospital resources - Mexico	197
Regulation and guidelines	198
Regulatory authorities	198
The Pan American Network for Drug Regulatory Harmonization (PANDRH)	198
ANVISA - Brazil	198
Brazilian Research Ethics Commission (CONEP)	199
ANMAT - Argentina	201
SSA - Mexico	202
COFEPRIS - Mexico	202
Clinical trial regulation	203
Brazil	204
Argentina	206
Mexico	208
Guidelines	209
Good Clinical Practices: Document of the Americas	209
The Buenos Aires Declaration on Ethics and Clinical Trials	212
Import licenses for drugs in clinical trials - Mexico	215
Outlook	216

Chapter 6 Central and Eastern Europe 218

Summary	218
Introduction	219
Geographic	219

	Czech Republic	220
	Poland	220
	Russian Federation	220
Political		220
	Czech Republic	220
	Poland	221
	Russian Federation	221
Economic		221
	Czech Republic	221
	Poland	221
	Russian Federation	222
Market dynamics		223
Vital statistics		223
	Population statistics	223
	Epidemiology and prevalence of major diseases	225
Pharmaceutical market		228
CRO market		230
	Czech Republic	230
	Poland	230
	Russian Federation	231
Clinical trial market		233
	Czech Republic	235
	Poland	235
	Russian Federation	236
Market drivers		238
Large eligible treatment naïve population who exhibit high retention rates		238
Large pool of dedicated, well trained and motivated investigators		239
Cost savings		239
Centralized healthcare systems and well-developed referral systems		240
Entry of Russian Federation into the World Trade Organization (WTO)		240
Positive assessments by the US FDA (Poland)		241
Key barriers		241
Poor hospital infrastructure with inadequate medical equipment		241
Cultural differences and issues		242
Potential delays importing the study drug (Russia)		242
Concerns and issues obtained from regulatory inspections by the FDA (Russia)		243
Lack of clinical trial experience amongst hospital staff and hospital services		244
Healthcare		245
Healthcare system – Czech Republic		245
Hospital resources – Czech Republic		246
Healthcare system – Poland		246
	Ministry of Health	247
	National health fund	247
	Territorial self-government administrations	247
Hospital resources – Poland		247
Healthcare system – Russian Federation		248
Hospital resources – Russian Federation		249
Regulation and legislation		250

Regulatory authorities	250
SUKL – Czech Republic	250
NIL – Poland	251
RZN – Russian Federation	252
Clinical trial regulation	253
Czech Republic	254
Poland	258
Russian Federation	258
Legislation	261
Poland removes tax block for clinical trials	261
Decree no. 226/2008 on good clinical practices - Czech Republic	261
Russia	261
Outlook	262

Appendix 264

Introduction to clinical trials	264
Clinical trial phases	264
Phase I	264
Phase II	264
Phase III	264
Phase IV	265
What is a clinical trial	265
Clinical trials of pharmaceutical agents	265
Types of clinical trial	266
Pilot studies	266
Proof of concept (PoC) trials	266
Randomized clinical studies	267
Controlled clinical trials	267
Parallel studies	267
Parallel group trials	267
Cohort studies	268
Case control studies	268
Role of the chief investigator	268
Clinical trial protocol and procedure	269
Determination of the clinical trial size	269
Role of the coordinating centre and trials unit	270
Role of the trial coordinator	270
The trial principle investigator	270
Forms and data management	270
Trial data analysis and evaluation	271
Ethical issues and conduct of clinical trial research	271
Interpretation and publication of clinical trial results	272
Principle regulatory agencies	272
The European Agency for the Evaluation of Medicinal Products (EMA)	272
The United States Food and Drug Administration (US FDA)	273
Japanese Ministry of Health, Labor and Welfare (MHLW)	273
Methodology statement	274

Primary Data and Information Gathering	274
Secondary data and information gathering	275
Definitions of Product-Life Cycle stages	277
Glossary of abbreviations and acronyms	277
Index	284

List of Figures

Figure 1.1:	Key issues facing Pharma and Biotech companies	26
Figure 1.2:	Cost of bringing a drug to market (\$m), 1975-2008	31
Figure 1.3:	Pharmaceutical R&D expenditure (\$bn), 2004-2009e	32
Figure 1.4:	Biotechnology R&D expenditure (\$bn), 2004-2009e	33
Figure 1.5:	Cost of clinical trials in the US (\$bn), 2005-2011e	33
Figure 2.6:	Comparison of locations across selected countries	48
Figure 2.7:	Korean Food and Drug Administration (KFDA) Approval Process	53
Figure 2.8:	CRO Segment Leaders	55
Figure 2.9:	Enhanced clinical site effectiveness (patients per site) in the emerging countries	58
Figure 2.10:	Fewer ineffective sites in the emerging countries	58
Figure 2.11:	Critical components for capacity building/conducting clinical trials	64
Figure 2.12:	Assessing clinical trial location feasibility	65
Figure 2.13:	CRO selection criteria	79
Figure 3.14:	GDP in India (%) by sector	86
Figure 3.15:	Projected growth of healthcare industry in India (\$bn), 2008-2022	86
Figure 3.16:	Population projection (millions) in India, 2000-2020	87
Figure 3.17:	Pharma industry in India (\$bn), 2007-2010	90
Figure 3.18:	Market share (%) between MNCs and local pharmaceutical companies in India, 2003-2007	91
Figure 3.10:	Growth of outsourced R&D to India by segment, 2009-14	96
Figure 3.20:	Clinical trials in India (by phase), 2009	97
Figure 3.21:	Types of disease and types of hospitals in India	100
Figure 3.22:	Cost of clinical trials (%) in India vs US	103
Figure 3.23:	Structure of healthcare system in India	109
Figure 3.24:	Current organogram of the Ministry of Health and Family Welfare	113
Figure 3.25:	Proposed organogram of the Ministry of Health and Family Welfare	114
Figure 3.26:	Approval categories of global clinical trials in India	119
Figure 4.27:	Administrative divisions of the People's Republic of China	135
Figure 4.28:	Pharma market in China (\$), 2007-2008	139
Figure 4.29:	CRO market in China (US\$), 2007-2012	141
Figure 4.30:	Cost of clinical trials (%) in China vs western countries	148
Figure 4.31:	The Chinese Healthcare System	155
Figure 4.32:	NRCMCS medical cover cost and benefits in China	157
Figure 4.33:	Current drug approval and evaluation process in China	163
Figure 4.34:	Application and approval procedure for clinical trials China	165
Figure 4.35:	Location of accredited sites for clinical trials in China	171
Figure 5.36:	Population projection ('000s) – Brazil, 2000-2050	178
Figure 5.37:	Population projection (thousands) – Argentina, 2000-2050	179
Figure 5.38:	Population projection (thousands) – Mexico, 2000-2050	181
Figure 5.39:	Forecast growth (\$bn) Latin America pharmaceutical market, 2008-2014	182

Figure 5.40:	Latin America pharmaceutical market 2008	183
Figure 5.41:	No. of clinical trials in Latin America, 2000-2008	186
Figure 5.42:	Clinical trials by phase in Latin America (number of trials), 2008	187
Figure 5.43:	Registered Research Ethics Committees (REC) by Region – Brazil 2008	201
Figure 5.44:	Regulation of clinical trials in Latin America 2007	203
Figure 5.45:	Regulatory flowchart - Brazil	205
Figure 5.46:	Regulatory flowchart - Argentina	207
Figure 5.47:	Regulatory flowchart - Mexico	209
Figure 6.48:	Pharmaceutical market by selected Central and Eastern European countries, 2007	228
Figure 6.49:	Clinical trials Europe	234
Figure 6.50:	Clinical trials by phase (no trials) in the Czech Republic, 2008	235
Figure 6.51:	Clinical trials market (\$m) in Poland, 2007-2010	236
Figure 6.52:	Clinical trials by therapy area (%) in Russia, 2008	237
Figure 6.53:	Clinical trials by phase (%) in Russia, 2008	238
Figure 6.54:	FDA inspection deficiencies in Russian sites	244

List of Tables

Table 2.1:	Demographics of selected emerging markets, 2007	50
Table 2.2:	Ethical principles & their application for research	72
Table 3.3:	Statistical healthcare data India	88
Table 3.4:	Ten leading causes of death (%) in India, 2002	88
Table 3.5:	Diseases of the developed world in India	89
Table 3.6:	Top 10 pharmaceutical companies (\$m) in India, 2008	92
Table 3.7:	Major biotechnology products in India and their companies	93
Table 3.8:	Major CROs operating in India	95
Table 3.9:	Major specialty hospital groups operating in Northern India	98
Table 3.10:	Regulatory authorities based in Northern India	99
Table 3.11:	Snapshot of hospitals in India	111
Table 4.12:	China Population Projections (m people), 1950-2050	137
Table 4.13:	Ten leading causes of death in China, 2002	137
Table 4.14:	Prevalence of major cancers in China, 2007	138
Table 4.15:	Top 10 pharmaceutical companies (\$m) in China, 2008	140
Table 4.16:	Major multinational CROs operating in China	142
Table 4.17:	Local Chinese owned CROs	145
Table 4.18:	Number of healthcare institutions according to ownership China	158
Table 4.19:	Total number of hospitals by ranking China	159
Table 4.20:	Chinese government agencies responsible for drug regulation	160
Table 5.21:	Ten leading causes of death, Argentina, 2003	180
Table 5.22:	Ten leading causes of death, Mexico, 2004 (compared to rate in 2000)	181
Table 5.23:	Top 10 pharma companies (\$m) in Brazil, Argentina, and Mexico, 2008	184
Table 5.24:	Major CROs operating in Latin America, 2009	185
Table 5.25:	Ten leading causes of death in Brazil, 2003	195
Table 5.26:	Snapshot of hospitals in Argentina, 2007	196
Table 6.27:	Central and Eastern Europe population projection (m people), 2009	223
Table 6.28:	Population statistics - Russia	224
Table 6.29:	Principle city population statistics – Russia, 2008	225
Table 6.30:	Estimated total deaths (thousands) by cause and by selected country	227
Table 6.31:	Top 10 pharmaceutical companies (\$m) in Russia, Poland and the Czech Republic, 2008	229
Table 6.32:	Major CROs operating in Eastern Europe (including Poland and Czech Republic), 2009	231
Table 6.33:	Top 10 Russian regions by no. of new investigative sites, 2006-2008	237
Table 6.34:	Snapshot of hospitals in the Czech Republic	246
Table 6.35:	Snapshot of hospitals in Poland	248
Table 6.36:	Contact details regulatory authorities in selected Central and Eastern European countries	251
Table 6.37:	Fees for clinical trial application (€) in the Czech Republic, April 2009	255
Table 6.38:	Guidelines and Forms for Clinical Trials Czech Republic	256
Table 6.39:	Checklist of documents for initial application in Czech Republic	257

